• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Hanson Bryan C converted options into 67,261 shares and covered exercise/tax liability with 26,468 shares, increasing direct ownership by 66% to 102,398 units (SEC Form 4)

    9/2/25 12:49:51 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hanson Bryan C

    (Last) (First) (Middle)
    2510 CONWAY AVE.
    3M CENTER BLDG. 275-6W

    (Street)
    MAPLEWOOD MN 55144

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Solventum Corp [ SOLV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/01/2025 M(1) 67,261 A $0 128,866 D
    Common Stock 09/01/2025 F 26,468 D $73.09 102,398 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 09/01/2025 M 67,261 (3) 09/01/2033 Common Stock 67,261 $0 67,261 D
    Explanation of Responses:
    1. Reflects vesting of Solventum RSUs received upon conversion of previously granted 3M RSUs. Each 3M RSU converted into the number of Solventum RSUs equal to the number of 3M Shares subject to such 3M RSU Award immediately prior to the Effective Time of the separation, multiplied by the SpinCo Ratio as set forth in the Employee Matters Agreement entered into in connection with the separation.
    2. Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.
    3. The RSUs shall fully vest in three tranches, with one-third vesting on each of the first through third anniversary of the grant date, subject to continued service through the vesting date.
    Remarks:
    /s/Matthew Rice, attorney-in-fact for Bryan C. Hanson 09/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SOLV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    7/15/2025$103.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    5/19/2025$87.00Neutral → Overweight
    Piper Sandler
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $SOLV
    SEC Filings

    View All

    Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    9/8/25 4:35:44 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    9/2/25 8:01:14 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    8/22/25 8:25:44 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

    Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

    1/8/25 6:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

    ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

    10/10/24 9:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports Second Quarter 2025 Financial Results

    Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

    8/7/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

    ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Aug. 7, 2025 Time: 3:30 p.m. CDT / 4:30 p.m. EDT Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (

    7/17/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports First Quarter 2025 Financial Results

    Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

    5/8/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers

    ST. PAUL, Minn., Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes"). The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025, as modified by Solventum's prior press release dated Sept. 8, 2025 increasing the Aggregate Cap, the Pool 1 Maximum Amount (as defined below) and the Tender SubCap (as defined below) (the "O

    9/8/25 2:30:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers

    ST. PAUL, Minn., Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap"). Solventum has amended the terms of the Tender Offers to (i) increase the Aggregate Cap from $1.75 billion to $2 billion, (ii) increase the previously announced Pool 1 Maximum Amount (as defined below) from $1.25 billion to $1.5 billion and (iii) within the upsized Pool 1 Maximum Amount, incre

    9/8/25 8:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business

    Highly Complementary Technologies Strengthen Thermo Fisher's Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE:SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment. The transaction includes Solventum's Purification & Filtration business serving Bioprocessing Filtration, Healthcare and Industrial Filtration, and Membranes1. The business s

    9/2/25 8:00:00 AM ET
    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Solventum upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Solventum from Equal-Weight to Overweight and set a new price target of $103.00

    7/15/25 8:30:16 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by Argus with a new price target

    Argus upgraded Solventum from Hold to Buy and set a new price target of $90.00

    7/1/25 8:13:22 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    KeyBanc Capital Markets initiated coverage on Solventum Corporation

    KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight

    6/6/25 8:37:20 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hanson Bryan C converted options into 67,261 shares and covered exercise/tax liability with 26,468 shares, increasing direct ownership by 66% to 102,398 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    9/2/25 12:49:51 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Large owner 3m Co sold $646,360,000 worth of shares (8,800,000 units at $73.45), decreasing direct ownership by 26% to 25,569,190 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    8/18/25 5:02:54 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Director Cox Carrie Smith converted options into 5,148 shares (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    5/15/25 4:23:40 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care